• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Clinical Trials

Gilead halts emergency access to COVID-19 contender remdesivir amid ‘overwhelming demand’

Since the early days of the current coronavirus outbreak, Gilead Sciences’ experimental antiviral drug remdesivir has been hailed as a leading hope. That halo has apparently overwhelmed the Big Biotech. Gilead has temporarily stopped granting patients emergency access to remdesivir under compassionate use due to an “exponential increase” in requests over the last few days,…

Oligomerix to Present at BIO CEO & Investor Conference, TAU2020 Global Conference

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO &…

Targeting Amyloid Oligomers for Alzheimer’s Research

Alzheimer’s disease is one of the most frightening diseases people can face. The deterioration of memory and comprehension and, ultimately death, is a terrifying concept. And little headway has been made in developing a treatment for this disease. But that could be changing. Biogen is likely on the road to having aducanumab approved as a…

Research Drug ‘chaperone’ fends off Alzheimer’s in mice by preventing toxic protein clumping

Alzheimer’s disease has long been associated with the harmful proteins amyloid beta and tau. They clump up in the brain, disrupting neurons and causing memory loss and other symptoms. Researchers at Temple University’s Lewis Katz School of Medicine say they’ve found a new way to prevent amyloid beta and tau from building up in the…

Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain

“This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans,” wrote Jonathan Kipnis of University of Virginia in Charlottesville. “These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing,” he added. More at:…

Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease

Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening second skeleton. Regeneron Pharmaceuticals believes it can offer hope: A new treatment reduced new bone growth by 90% in a clinical trial, the company said, a result that could lead to Food and Drug Administration approval. More at:  https://www.statnews.com/2020/01/09/regeneron-drug-reduces-bone-growth-rare-skeletal-disease/

Biogen’s Alzheimer’s drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

UPDATED: Biogen’s Alzheimer’s drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads   More at https://endpts.com/biogens-alzheimers-drug-aducanumab-implodes-in-a-phiii-disaster/ 

UC Irvine medical study gives hope to Orange County mom with ALS

She began seeing a physical therapist and stopped working out. Then in early 2017 came the limp — what the therapist termed “drop foot.” The next several months were filled with doctor visits, nerve tests, a broken leg and further weakening of Wittenberg’s limbs. By March of that year, the mother of two could no…

New Study Reveals Two Genes Associated with High Risk for ALS

Genetic mutations in two previously unrecognized genes, the microtubule-associated protein tau (MAPT) and BNIP1 genes, are associated with elevated risk for amyotrophic lateral sclerosis (ALS). The study with that finding “Selective genetic overlap between amyotrophic lateral sclerosis and diseases of the frontotemporal dementia spectrum,” was published in the journal JAMA Neurology. As seen in other neurodegenerative diseases, abnormal accumulation of…

Democrats sink House vote on Trump-backed drug bill

House Republicans failed Tuesday evening to pass a “right-to-try” bill that would give terminally ill patients access to experimental drugs without FDA authorization after failing to muster enough votes to approve it through an expedited process. The 259-140 vote fell short of the necessary two-thirds support from the House chamber. The failed vote is a…